Konferenssiposteri

Imaging pro‐inflammatory microglia in Parkinson’s disease using [11C]SMW139 PET: a multi‐center study




TekijätRikken, Roos M.; van de Giessen, Elsmarieke; Brumberg, Joachim; Aarnio, Richard; Joling, Merijn; Forsberg Morén, Anton; Kerstens, Vera; Moein, Mohammad M.; Nag, Sangram; Halldin, Christer; Fazio, Patrik; Roos, Dareia S.; Berendse, Henk W.; Kassiou, Michael; Wahlroos, Saara; Haaparanta‐Solin, Merja; Oikonen, Vesa; Schuit, Robert C.; Boellaard, Ronald; Windhorst, Albert D.; Jacobs, Andreas H.; Lammertsma, Adriaan A.; Rinne, Juha O.; Varrone, Andrea; Golla, Sandeep S. V.

KustantajaJohn Wiley & Sons

Julkaisuvuosi2025

Lehti: Alzheimer's and Dementia

Artikkelin numeroe108572

Vuosikerta21

Numero57

ISSN1552-5260

eISSN1552-5279

DOIhttps://doi.org/10.1002/alz70861_108572

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Kokonaan avoin julkaisukanava

Verkko-osoitehttps://doi.org/10.1002/alz70861_108572

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/508349834

Rinnakkaistallenteen lisenssiCC BY

Rinnakkaistallennetun julkaisun versioKustantajan versio


Tiivistelmä

Background:
Several TSPO PET studies have shown increased glial cell density inParkinson’s disease (PD). However, TSPO PET cannot discriminate between pro- andanti-inflammatory microglia, thereby limiting the understanding of pro-inflammatorycontributions to PD pathogenesis. Therefore, this study focused on the novelradiotracer [11 C]SMW139 targeting the P2X7 receptor (P2X7R), which is specificallyexpressed on pro-inflammatory microglia. We aim to investigate pro-inflammatorysignals in PD using [11C]SMW139 PET.

Method:
15 PD patients (age: 67, 67% male) and 15 controls (HC) (age: 64,47% male) were included from Amsterdam UMC, Turku University Hospital andKarolinska Institutet. All participants underwent a 90 min [11 C]SMW139 PET scanwith arterial sampling, resulting in the outcome measure VTp (Volume of distribution).[ 11 C]SMW139 VTp was quantified in several regions of interest (ROIs)(Figure 1).Differences in [11 C]SMW139 VTp between PD and HC were assessed using linearmixed models with post hoc testing. Associations between motor symptom severity asmeasured by UPDRS-III, disease duration and [11 C]SMW139 VTp were assessed usinglinear regressions.

Result:
In the a-priori ROIs, PD patients showed significantly higher VTp in the putamen(β=0.04, p =0.046) and whole cortex (β= 0.04, p =0.043) compared to HC, indicatinghigher pro-inflammatory activity (Figure 1). In an exploratory analysis, PD patients also showed higher VTp in the orbitofrontal cortex (β= 0.04, p =0.041). There wasno significant association between VTp and symptom severity (brainstem: β=-0.002,p =0.084; caudate nucleus; β= -0.002, p = 0.164800; putamen: β= -0.002, p =0.265,whole cortex: β= -0.002, p =0.119) or disease duration in PD (brainstem: β= -0.01, p=0.055; caudate nucleus; β= -0.005, p = 0.282; putamen: β= -0.01, p =0.113, wholecortex: β= -0.007, p =0.217) (Figure 2). However, there was a negative trend indicatinghigher pro-inflammatory activation earlier in the disease trajectory, which warrantsfurther investigation (Figure 2 & 3).

Conclusion:
​​​​​​​PD patients showed increased P2X7R binding in the putamen and braincortex, as assessed by [ 11 C]SMW139 PET, suggesting the presence of increased levelsof pro-inflammatory microglia.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on